Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial

Eupraxia Pharmaceuticals, Inc. ((TSE:EPRX)) announced an update on their ongoing clinical study.

Study Overview: Eupraxia Pharmaceuticals, Inc. is conducting a Phase 1b/2 trial titled ‘A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE).’ The study aims to assess the safety, efficacy, and pharmacokinetics of EP-104GI, with endoscopic and histologic assessments to evaluate its local effects on eosinophilic esophagitis (EoE) disease activity. This research is significant as it explores a potential new treatment for EoE, a chronic immune system disease.

Intervention/Treatment: The intervention being tested is EP-104GI, an extended-release fluticasone propionate for injectable suspension intended for gastrointestinal administration. The purpose of this treatment is to manage EoE by reducing inflammation in the esophagus.

Study Design: This interventional study employs a randomized, crossover design with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment, focusing on determining the optimal dosing regimen of EP-104GI.

Study Timeline: The study commenced on October 19, 2022, and is currently recruiting participants. The last update was submitted on August 6, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.

Market Implications: The ongoing study could influence Eupraxia Pharmaceuticals’ stock performance positively if results demonstrate significant efficacy and safety of EP-104GI. Investors may view this as a promising advancement in the treatment of EoE, potentially impacting the competitive landscape as other companies may seek to develop similar treatments.

The study is ongoing, and further details are available on the ClinicalTrials portal.